Literature DB >> 28799875

Direct versus indirect bypasses for adult ischemic-type moyamoya disease: a propensity score-matched analysis.

Xiaofeng Deng1,2, Faliang Gao1,2, Dong Zhang1,2, Yan Zhang1,2, Rong Wang1,2, Shuo Wang1,2, Yong Cao1,2, Yuanli Zhao1,2, Yuesong Pan3,4, Xingju Liu1,2, Qian Zhang1,2, Jizong Zhao1,2.   

Abstract

OBJECTIVE The optimal surgical modality for moyamoya disease (MMD) remains unclear. The aim of this study was to compare the surgical effects of direct bypass (DB) and indirect bypass (IB) in the treatment of adult ischemic-type MMD. METHODS Adult patients with ischemic-type MMD who underwent either DB or IB from 2009 to 2015 were identified retrospectively from a prospective database. Patients lost to follow-up or with a follow-up period less than 12 months were excluded. Recurrent stroke events and modified Rankin Scale (mRS) scores at the last follow-up were compared between the 2 surgical groups after 1:1 propensity score matching. RESULTS A total of 220 patients were considered, including 143 patients who underwent DB and 77 patients who underwent IB. After propensity score matching, 70 pairs were obtained. The median follow-up period was 40.5 months (range 14-75 months) in the DB group and 31.5 months (range 14-71 months) in the IB group (p = 0.004). Kaplan-Meier analysis showed that patients who received DB had a longer stroke-free time (mean 72.1 months) compared with patients who received IB (mean 61.0 months) (p = 0.045). Good neurological status (mRS score ≤ 2) was achieved in 64 patients in the DB group (91.4%) and 66 patients in the IB group (94.3%), but there was no significant difference (p = 0.512). CONCLUSIONS Although neurological function outcome was not determined by the surgical modality, DB is more effective in preventing recurrent ischemic strokes than IB for adult ischemic-type MMD.

Entities:  

Keywords:  CB = combined bypass; DB = direct bypass; DSA = digital subtraction angiography; IB = indirect bypass; MMD = moyamoya disease; PCA = posterior cerebral artery; QALY = quality-adjusted life year; TIA = transient ischemic attack; direct bypass; indirect bypass; mRS = modified Rankin Scale; moyamoya disease; revascularization; stroke; vascular disorders

Mesh:

Year:  2017        PMID: 28799875     DOI: 10.3171/2017.2.JNS162405

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  21 in total

1.  Supraorbital keyhole versus pterional craniotomies for ruptured anterior communicating artery aneurysms: a propensity score-matched analysis.

Authors:  Le-Bao Yu; Zheng Huang; Ze-Guang Ren; Jun-Shi Shao; Yan Zhang; Rong Wang; Dong Zhang
Journal:  Neurosurg Rev       Date:  2018-11-10       Impact factor: 3.042

2.  High variance of intraoperative blood pressure predicts early cerebral infarction after revascularization surgery in patients with Moyamoya disease.

Authors:  Jiaxi Li; Yahui Zhao; Meng Zhao; Penghui Cao; Xingju Liu; Hao Ren; Dong Zhang; Yan Zhang; Rong Wang; Jizong Zhao
Journal:  Neurosurg Rev       Date:  2019-06-15       Impact factor: 3.042

Review 3.  Surgical Treatment of Adult Moyamoya Disease.

Authors:  Si Un Lee; Chang Wan Oh; O-Ki Kwon; Jae Seung Bang; Seung Pil Ban; Hyoung Soo Byoun; Tackeun Kim
Journal:  Curr Treat Options Neurol       Date:  2018-05-28       Impact factor: 3.598

4.  Hyperhomocysteinemia is a risk factor for postoperative ischemia in adult patients with moyamoya disease.

Authors:  Junsheng Li; Peicong Ge; Qian Zhang; Fa Lin; Rong Wang; Yan Zhang; Dong Zhang; Wen Wang; Jizong Zhao
Journal:  Neurosurg Rev       Date:  2021-01-27       Impact factor: 3.042

5.  Challenging direct bypass surgery for very young children with moyamoya disease: technical notes.

Authors:  Yoshio Araki; Kenji Uda; Kinya Yokoyama; Fumiaki Kanamori; Michihiro Kurimoto; Yoshiki Shiba; Takashi Mamiya; Masahiro Nishihori; Kazuhito Takeuchi; Kuniaki Tanahashi; Yuichi Nagata; Yusuke Nishimura; Sho Okamoto; Masaki Sumitomo; Takashi Izumi; Ryuta Saito
Journal:  Neurosurg Rev       Date:  2021-10-31       Impact factor: 3.042

6.  Angiographic Characteristics of Cerebral Perfusion and Hemodynamics of the Bridging Artery After Surgical Treatment of Unilateral Moyamoya Disease.

Authors:  Kun Zhang; Wei Ren; Yu-Xue Sun; Xin-Jun Wang; Chao-Yue Li; Zi-Liang Wang; Tian-Xiao Li; Bu-Lang Gao
Journal:  Front Neurosci       Date:  2022-06-14       Impact factor: 5.152

7.  2021 Japanese Guidelines for the Management of Moyamoya Disease: Guidelines from the Research Committee on Moyamoya Disease and Japan Stroke Society.

Authors:  Miki Fujimura; Teiji Tominaga; Satoshi Kuroda; Jun C Takahashi; Hidenori Endo; Kuniaki Ogasawara; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2022-02-22       Impact factor: 2.036

8.  Multimodal neuronavigation-guided precision bypass in adult ischaemic patients with moyamoya disease: study protocol for a randomised controlled trial.

Authors:  Junlin Lu; Yahui Zhao; Li Ma; Yu Chen; Mingtao Li; Xun Ye; Rong Wang; Xiaolin Chen; Yuanli Zhao
Journal:  BMJ Open       Date:  2019-03-20       Impact factor: 2.692

9.  Clinical Features, Surgical Treatment, and Long-Term Outcome of a Multicenter Cohort of Pediatric Moyamoya.

Authors:  Jun Zheng; Le-Bao Yu; Ke-Fang Dai; Yan Zhang; Rong Wang; Dong Zhang
Journal:  Front Neurol       Date:  2019-01-22       Impact factor: 4.003

10.  Use of a panel of four microRNAs in CSF as a predicted biomarker for postoperative neoangiogenesis in moyamoya disease.

Authors:  Gang Wang; Yunyu Wen; Siyuan Chen; Guozhong Zhang; Mingzhou Li; Shichao Zhang; Songtao Qi; Wenfeng Feng
Journal:  CNS Neurosci Ther       Date:  2021-05-04       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.